ZennCell Obtains European Patent for Eye Health Functional Ingredient

Domestic MFDS 'Individual Recognition' Approval
Expected to Replace Existing Eye Health Market

Genensel announced on the 9th that it has obtained a European patent for a functional ingredient effective in improving eye health, including the prevention of retinal diseases. The patent is for Genensel's self-developed natural material, 'Centella Asiatica Extract (CA-HE50)'.

This ingredient functions to maintain the macular pigment optical density (MPOD) of the eye, which can decrease due to aging, and protects retinal pigment epithelial cells. The official patent name is "Composition for preventing or treating retinal disease, containing centella asiatica extract."

Genensel had already obtained two patents for the same material in South Korea in 2020 and 2021. Currently, patent applications are also underway in the United States, China, and Japan.

In preclinical trials, administration of the patented material to mice with damaged macula in retinal tissue showed excellent cell regeneration efficacy. In human clinical trials, macular degeneration improved by approximately 14% compared to before intake and placebo.

A Genensel representative stated, "We have signed contracts with manufacturers to launch health functional foods using the patented material," adding, "We are in discussions with multiple companies regarding sales."

They further explained, "Since it helps increase macular pigment density as well as tissue regeneration, it enables fundamental eye health management," and added, "It also has significant preventive effects such as protecting retinal pigment epithelial cells." The company emphasized that there are no side effects from long-term use.

Genensel completed human clinical trials for the patented material in December 2021 and received approval from the Ministry of Food and Drug Safety as an 'Individually Recognized Functional Ingredient.'

This content was produced with the assistance of AI translation services.